News Search Results
Mar 19, 2026, 09:00 ET HighVista Appoints Raudel Yanez to Launch GP-Led Secondaries Strategy
span private markets, including private credit, lower middle market private equity, and early-stage venture capital; public markets, including biotechnology equities and hedged public markets strategies; as well as multi-asset alternatives.Important DisclosureThe views and options
More news about: HighVista Strategies LLC
Mar 19, 2026, 09:00 ET Congruence Announces First Dosing in Phase 1/1b Clinical Trial of CGX-926, a First-in-Class Oral MC4R Corrector for Genetic Obesity
and repeatable value creation paradigm.About Congruence TherapeuticsCongruence is a clinical-stage, computationally driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Their proprietary
More news about: Congruence Therapeutics
Mar 19, 2026, 08:30 ET Bambusa Therapeutics Appoints Todd James Chief Financial Officer
Professional in Biotechnology.Earlier in his career, Mr. James spent nine years at Trout Group and Trout Capital, where he advised biopharmaceutical companies on investor relations, capital raising, and corporate strategy. He began his career on Wall Street within the Biotechnology Capital Markets
More news about: Bambusa Therapeutics, Inc.
Mar 19, 2026, 08:30 ET Clearsight Advises Stratis Group in its Acquisition by Nexus Health, part of The Lockwood Group
Stratis Group is a consulting firm specializing in commercialization strategy, market access, patient services, and analytics for pharmaceutical, biotechnology, and physician network clients. Founded in 2014, the Company brings a differentiated, data-driven approach to commercialization by combining advanced
More news about: Clearsight Advisors
Mar 19, 2026, 08:10 ET Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer
NANTONG, China, March 19, 2026 /PRNewswire/ -- Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced that China's National Medical Products Administration (NMPA)
More news about: Ractigen Therapeutics
Mar 19, 2026, 08:00 ET Antheia Appoints Dr. Chris Savile as Vice President of Business Development and Partnerships
our team. His proven track record of translating complex biotechnology into meaningful business opportunities will be critical to expanding the impact of our platform."Savile brings more than 20 years of experience across biotechnology and industrial biosynthesis. Most recently, he served as President
More news about: Antheia
Mar 19, 2026, 08:00 ET Hanskin Lands in 1,400 ULTA Beauty Stores, Bringing Glass Skin Hydration to the U.S.
firming care, and glow-enhancing benefits, representing a new evolution of PDRN-powered skincare innovation.The serum also incorporates biotechnology-driven ingredient purification and stabilization processes developed by Celltrion Skincure, optimizing the molecular design and delivery efficiency
More news about: Hanskin
Mar 19, 2026, 08:00 ET Kalohexis Emerges from Stealth to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic Diseases
NORTHBROOK, Ill., March 19, 2026 /PRNewswire/ -- Kalohexis, a newly created biotechnology company to advance the clinical development of a portfolio of drug candidates harnessing the melanocortin (MC) system for the treatment of metabolic
More news about: Kalohexis
Mar 19, 2026, 08:00 ET Endevica Announces Spinout of Kalohexis to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic Diseases
privately-held company developing first-in-class synthetic peptidomimetics, today announced the spinout and launch of Kalohexis, a newly created biotechnology company to advance the clinical development of a portfolio of drug candidates harnessing the melanocortin (MC) system for the treatment of metabolic
More news about: Endevica Bio
Mar 19, 2026, 07:50 ET Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
therapeutics, and the owner of Scinai Biopharma Services Ltd., a rapidly expanding contract development and manufacturing organization (CDMO) serving biotechnology and pharmaceutical companies, today announced its participation in BIO-Europe Spring® 2026, taking place March 23–25 in Lisbon, Portugal.
More news about: Scinai Immunotherapeutics Ltd.
Mar 19, 2026, 07:30 ET Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Mar 19, 2026, 07:00 ET Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
March 19, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
Mar 19, 2026, 07:00 ET Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
Brii Biosciences Limited ("Brii Bio," "Brii," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today provided a corporate update
More news about: Brii Biosciences Limited
Mar 19, 2026, 06:45 ET Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Mar 19, 2026, 03:38 ET Animal Regenerative Therapies Market Worldwide to Reach USD 870 Million by 2032, Driven by Advancements in Veterinary Biotechnology | Vyansa Intelligence
well-established veterinary healthcare infrastructure, high expenditure on companion animal care, and the strong presence of leading pharmaceutical and biotechnology companies. The region also benefits from increasing clinical adoption of regenerative therapies and ongoing research activities aimed at expanding
More news about: Vyansa Intelligence
Mar 19, 2026, 03:01 ET Europe Cosmetic Ingredients Market Forecast to Reach USD 14.22 Billion by 2032, Driven by Skin Care Innovation | MarkNtel Advisors
cosmetic formulations, is encouraging ingredient manufacturers and biotechnology firms to focus on alternative raw materials that reduce environmental impact while maintaining high product performance. As a result, innovation in biotechnology-driven ingredients and sustainable formulation solutions is becoming
More news about: MarkNtel Advisors
Mar 18, 2026, 20:00 ET SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Extensive Stage Small Cell Lung Cancer at ELCC 2026
REDMOND, Wash., March 18, 2026 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced an abstract for iza-bren (izalontamab brengitecan), a potentially first-in-class EGFRxHER3 bispecific antibody drug conjugate
More news about: SystImmune, Inc.
Mar 18, 2026, 15:43 ET Genome Canada and Ontario Genomics Award Specific Biologics and Western University $1.8 Million Grant to Develop a Machine Learning Platform to Accelerate the Development of the Company's Dualase®-based Therapeutics
TORONTO, March 18, 2026 /PRNewswire/ - Specific Biologics Inc. ("Specific"), a biotechnology company developing industry-leading in vivo genome editing medicines to treat the untreatable, today announced that together with Western
More news about: Specific Biologics Inc.
Mar 18, 2026, 15:43 ET Genome Canada and Ontario Genomics Award Specific Biologics and Western University $1.8 Million Grant to Develop a Machine Learning Platform to Accelerate the Development of the Company's Dualase®-based Therapeutics
TORONTO, March 18, 2026 /CNW/ - Specific Biologics Inc. ("Specific"), a biotechnology company developing industry-leading in vivo genome editing medicines to treat the untreatable, today announced that together with Western
More news about: Specific Biologics Inc.
Mar 18, 2026, 11:32 ET Hilco Global Seeks Offers to Acquire Non-Core Patent Portfolio of Locus Fermentation Solutions
monetization services, announced that it is seeking offers to acquire the non-core patent portfolio of Locus Fermentation Solutions, a Solon, Ohio-based biotechnology company known for its innovative fermentation-enabled technologies. The offering invites interested parties to submit non-binding indications of
More news about: Hilco Trading, LLC
Mar 18, 2026, 11:06 ET Diakonos Oncology to Showcase DOC1021 (dubodencel) Clinical Data in Pancreatic Cancer and Glioblastoma at AACR and AAN 2026
Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, announced today that the Company will present
More news about: Diakonos Oncology
Mar 18, 2026, 10:44 ET /C O R R E C T I O N -- NeuroSense/
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that Dr. Christian Lunetta will
More news about: NeuroSense
Mar 18, 2026, 10:00 ET A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
more than $45 billion by 2035. And at the intersection of regenerative medicine and longevity science, a small biotechnology company just hit a manufacturing milestone that turns the Klotho thesis from laboratory theory into production reality.Avaí Bio (OTCQB: AVAI)
More news about: Equity Insider
Mar 18, 2026, 09:00 ET Sumitomo Corporation do Brasil and Cemvita Partner to Integrate production of Bio-Methane and Bio-Oil, a precursor of SAF in Brazil
the future of bioenergy, not as single-product projects, but as integrated systems," said Moji Karimi, CEO of Cemvita. "By combining Cemvita's biotechnology platform with Sumitomo's global infrastructure capabilities and market access, we can unlock higher-value, lower-carbon outcomes from waste streams
More news about: Sumitomo Corporation do Brasil S.A.
Mar 18, 2026, 09:00 ET Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics
More news about: Roche Diagnostics